|
PART
|
96T
|
48T
|
STORAGE
|
|
Pre-Coated Plate
|
8×12
|
8×6
|
4 ℃ / -20 ℃
|
|
Pre-Mixed Standards
|
2 vials
|
1 vial
|
4 ℃ / -20 ℃
|
|
Pre-Mixed Biotinylated Antibody (1:100)
|
1 vial
|
1 vial
|
4 ℃ / -20 ℃
|
|
Enzyme Conjugate(1:100)
|
1 vial
|
1 vial
|
4 ℃ / -20 ℃
|
|
Enzyme Diluent
|
1 vial
|
1 vial
|
4 ℃ / -20 ℃
|
|
Antibody Diluent
|
1 vial
|
1 vial
|
4 ℃ / -20 ℃
|
|
Standard Diluent
|
1 vial
|
1 vial
|
4 ℃ / -20 ℃
|
|
Sample Diluent
|
1 vial
|
1 vial
|
4 ℃ / -20 ℃
|
|
Washing Buffer (1:25)
|
1 vial
|
1 vial
|
4 ℃ / -20 ℃
|
|
Color Reagent A
|
1 vial
|
1 vial
|
4 ℃ / -20 ℃
|
|
Color Reagent B
|
1 vial
|
1 vial
|
4 ℃ / -20 ℃
|
|
Color Reagent C
|
1 vial
|
1 vial
|
4 ℃ / -20 ℃
|
|
Manual
|
1 set
|
1 set
|
RT
|
Place collected whole blood in refrigerator at 4 ℃ overnight. Then centrifuge for 10mins at 1000-3000 rpm. Take supernatant and either test immediately or place samples at -20 ℃/-80 ℃(1-3 months) for storage.
Take plasma where EDTA, sodium citrate, or heparin has been added as anticoagulant. Mix well. Centrifuge mixture for 10mins at 1000-3000 rpm. Take supernatant and test immediately or place samples at -20 ℃ /-80 ℃ (1-3 months) for storage.
Take tissue slices which have been washed in 0.01 M PBS and then a tissue protein extraction reagent has been added according to proportion of 1 g to 5-10 mL and then mixed on ice bath. After sufficient homogenization, please then centrifuge for 10mins at 5000-10000 rpm. Take supernatant for immediate testing, or place samples at -20 ℃/-80 ℃ (1-3 months) for storage.
Centrifuge for 10 mins at 1000-3000 rpm. Take supernatant for immediate testing, or place samples at -20 ℃/-80 ℃ (1-3 months) for storage.
Centrifuge for 10mins at 1000-3000 rpm. Take supernatant for immediate testing, or place samples at -20 ℃/-80 ℃ (1-3 months) for storage.
|
TYPICAL DATA
|
Reference STD1
|
Reference STD2
|
Reference STD3
|
Reference STD4
|
Reference STD5
|
Reference STD6
|
Reference STD7
|
Reference STD8
|
|
SARS-CoV-2 N IgG+M, ng/mL
|
32
|
16
|
8
|
4
|
2
|
1
|
0.5
|
0
|
|
SARS-CoV-2 N IgG+M, OD.
|
3.669
|
1.999
|
1.077
|
0.605
|
0.336
|
0.193
|
0.104
|
0.072
|
|
SARS-CoV-2 N IgM, ng/mL
|
10
|
5
|
2.5
|
1.25
|
0.625
|
0.313
|
0.156
|
0
|
|
SARS-CoV-2 N IgM, OD.
|
2.325
|
1.241
|
0.731
|
0.387
|
0.219
|
0.122
|
0.069
|
0.045
|
|
Q fever IgM, ng/mL
|
32
|
16
|
8
|
4
|
2
|
1
|
0.5
|
0
|
|
Q fever IgM, OD.
|
2.288
|
1.222
|
0.671
|
0.373
|
0.218
|
0.118
|
0.064
|
0.043
|
|
EV71 IgG, ng/mL
|
32
|
16
|
8
|
4
|
2
|
1
|
0.5
|
0
|
|
EV71 IgG, OD.
|
3.226
|
1.757
|
1.026
|
0.57
|
0.301
|
0.169
|
0.095
|
0.063
|
STANDARD CURVE
To assess linearity of the assay, samples were spiked with high concentrations of Rat SARS-CoV-2 N IgG+M, SARS-CoV-2 N IgM, Q fever IgM, EV71 IgG and diluted with the appropriate calibrator diluent to produce samples with values within the dynamic range of the assay.
|
Matrix
|
Scope %
|
Average % Recovery Rate
|
|
serum(n=5)
|
85-90
|
87.5
|
|
EDTA plasma(n=5)
|
91-98
|
94.5
|
|
Cell Culture Media(n=5)
|
91-109
|
100
|
|
Within-Run Precision
|
Inter-Batch Precision
|
|||||
|
Sample
|
1
|
2
|
3
|
1
|
2
|
3
|
|
n
|
20
|
20
|
20
|
20
|
20
|
20
|
|
CV%
|
6.4
|
6
|
6.2
|
8.9
|
9
|
8.8
|